Mealey's (June 3, 2020, 2:07 PM EDT) -- SAN DIEGO — A federal judge in California on June 1 ruled that although the lead plaintiff in a securities class action lawsuit against a biopharmaceutical company and certain of its current and former senior executives has failed to sufficiently show that certain of the defendants’ alleged misrepresentations made regarding the safety and commercialization of the company’s Parkinson’s disease psychosis (PD psychosis) treatment drug were actionable, he properly pleaded that others were actionable and made with the requisite scienter (In re Acadia Pharmaceuticals Inc. Securities Litigation, No. 18-1647, S.D. Calif., 2020 U.S. Dist. LEXIS 95464)....